These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7920172)

  • 1. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent status of the antisense oligonucleotide approaches in oncology.
    Ma L; Calvo F
    Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Applications of antisense oligonucleotides in oncology].
    Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
    Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides.
    Calabretta B; Skorski T; Zon G
    Semin Cancer Biol; 1992 Dec; 3(6):391-8. PubMed ID: 1286160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo.
    Nakashiro K; Kawamata H; Hino S; Uchida D; Miwa Y; Hamano H; Omotehara F; Yoshida H; Sato M
    Cancer Res; 1998 Feb; 58(3):549-55. PubMed ID: 9458104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense therapy for cancer.
    Gleave ME; Monia BP
    Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRE-palindrome oligonucleotide as a transcription factor decoy and an inhibitor of tumor growth.
    Cho-Chung YS
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):167-70. PubMed ID: 9593058
    [No Abstract]   [Full Text] [Related]  

  • 16. Antisense inhibition of oncogene expression.
    Neckers L; Whitesell L; Rosolen A; Geselowitz DA
    Crit Rev Oncog; 1992; 3(1-2):175-231. PubMed ID: 1312868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors.
    Kitange G; Shibata S; Tokunaga Y; Yagi N; Yasunaga A; Kishikawa M; Naito S
    Lab Invest; 1999 Apr; 79(4):407-16. PubMed ID: 10211993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A novel paradigm and new targets in cancer therapy].
    Novik AA; Kamilova TA; Tsygan VN
    Vopr Onkol; 2003; 49(6):695-704. PubMed ID: 14976912
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications.
    Calabretta B
    Cancer Res; 1991 Sep; 51(17):4505-10. PubMed ID: 1873794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.